- Report
- March 2024
- 50 Pages
Global
From €2545EUR$2,650USD£2,173GBP
- Report
- March 2024
- 193 Pages
Global
From €3241EUR$3,374USD£2,766GBP
€3601EUR$3,749USD£3,074GBP
- Report
- February 2024
- 200 Pages
Global
From €4802EUR$5,000USD£4,100GBP
- Report
- January 2024
- 80 Pages
United States
From €3361EUR$3,500USD£2,870GBP
- Report
- June 2023
- 86 Pages
United States
From €5715EUR$5,950USD£4,878GBP
- Drug Pipelines
- October 2021
- 60 Pages
Global
From €2401EUR$2,500USD£2,050GBP
- Report
- April 2022
- 21 Pages
Ireland
- Report
- February 2024
- 111 Pages
Global
From €3500EUR$3,904USD£3,093GBP
- Report
- January 2024
- 91 Pages
Global
From €3500EUR$3,904USD£3,093GBP
- Report
- May 2023
- 147 Pages
Global
From €5762EUR$5,999USD£4,919GBP
Cannabinol (CBN) is a naturally occurring cannabinoid found in the cannabis plant. It is known to have analgesic properties, which makes it a potential therapeutic option for pain relief. CBN has been studied for its potential to reduce inflammation and act as an anti-inflammatory agent. It has also been studied for its potential to reduce anxiety and depression.
CBN is gaining traction in the analgesic market due to its potential to provide relief from pain without the psychoactive effects of THC. It is being studied for its potential to treat a variety of conditions, including chronic pain, arthritis, and fibromyalgia.
The CBN market is growing rapidly, with more companies entering the space and offering products containing CBN. Companies such as Charlotte's Web, Elixinol, and Endoca are leading the way in the CBN market, offering products such as tinctures, capsules, and topical creams. Other companies such as Kannaway and PlusCBD are also offering CBN products. Show Less Read more